SG Americas Securities LLC Raises Stock Position in Zymeworks Inc. (NYSE:ZYME)

SG Americas Securities LLC boosted its holdings in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 266.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 98,165 shares of the company's stock after buying an additional 71,383 shares during the quarter. SG Americas Securities LLC owned 0.14% of Zymeworks worth $1,169,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Deutsche Bank AG grew its position in shares of Zymeworks by 1.2% during the fourth quarter. Deutsche Bank AG now owns 1,546,772 shares of the company's stock worth $22,645,000 after buying an additional 17,849 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Zymeworks by 14.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 972,742 shares of the company's stock worth $14,240,000 after acquiring an additional 123,240 shares in the last quarter. Bridgeway Capital Management LLC grew its holdings in Zymeworks by 2.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 759,653 shares of the company's stock worth $11,121,000 after acquiring an additional 17,092 shares in the last quarter. Blackstone Inc. increased its position in shares of Zymeworks by 2,171.4% in the 4th quarter. Blackstone Inc. now owns 569,715 shares of the company's stock valued at $8,341,000 after purchasing an additional 544,633 shares during the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Zymeworks in the 4th quarter valued at $6,629,000. Hedge funds and other institutional investors own 92.89% of the company's stock.

Zymeworks Stock Down 1.0%

ZYME traded down $0.13 on Friday, hitting $12.50. 269,428 shares of the company traded hands, compared to its average volume of 550,499. Zymeworks Inc. has a 12-month low of $8.21 and a 12-month high of $17.70. The company has a 50 day moving average of $12.01 and a 200-day moving average of $12.91. The stock has a market capitalization of $869.99 million, a PE ratio of -8.31 and a beta of 1.18.

Zymeworks (NYSE:ZYME - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. The firm had revenue of $27.11 million during the quarter, compared to the consensus estimate of $20.65 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The company's revenue for the quarter was up 170.3% on a year-over-year basis. During the same period last year, the company earned ($0.42) earnings per share. On average, research analysts anticipate that Zymeworks Inc. will post -1.39 EPS for the current year.

Insider Transactions at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc acquired 22,689 shares of the business's stock in a transaction on Monday, March 24th. The stock was purchased at an average price of $13.08 per share, for a total transaction of $296,772.12. Following the completion of the transaction, the director now owns 17,157,802 shares of the company's stock, valued at $224,424,050.16. The trade was a 0.13% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 471,106 shares of company stock worth $5,421,364 over the last ninety days. 1.92% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ZYME. Lifesci Capital started coverage on shares of Zymeworks in a research note on Tuesday, March 11th. They set an "outperform" rating and a $30.00 target price for the company. TD Cowen started coverage on Zymeworks in a report on Tuesday, May 20th. They issued a "buy" rating on the stock. HC Wainwright raised their target price on Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Monday, March 10th. Citigroup upped their price target on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, March 7th. Finally, TD Securities assumed coverage on shares of Zymeworks in a report on Tuesday, May 20th. They set a "buy" rating on the stock. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $21.00.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.